SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Stull, D. M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Current Trends in the Treatment of Acute and Chronic Myelogenous Leukemia

Dawn Marie Stull, PharmD, BCOP

New York-Presbyterian Hospital, New York Weill Cornell Center, 525 E 68th St, New York, NY 10021-4830, dmstull{at}nyp.org

Acute myelogenous and chronic myelogenous leukemia are uniformly fatal if left untreated. Treatment with conventional chemotherapeutic agents results in a cure for a small percentage of patients and substantial toxicities in all patients that receive treatment. The first of a new generation of "targeted therapies" has recently been introduced. It is hoped that these agents will demonstrate enhanced efficacy and a decreased toxicity profile. Gemtuzumab ozogamicin (MylotargTM) is the first antibody-targeted therapy approved for use in patients with acute myelogeneous leukemia, arsenic trioxide (Trisenox®) has demonstrated efficacy in patients with acute promyelocytic leukemia, and imatinib mesylate (GleevecTM) has proven efficacy in patients with chronic myelogenous leukemia. Initially, these agents were granted FDA approval for use in those who were refractory to or intolerant of conventional treatment options. Research is ongoing to further define the full therapeutic potential of these agents and to discover additional targeted therapies with increased efficacy.

Key Words: leukemia • acute myelogenous • chronic myelogenous • imatinib mesylate • gemtuzumab ozogamicin • arsenic trioxide

Journal of Pharmacy Practice, Vol. 15, No. 1, 62-74 (2002)
DOI: 10.1106/UJQK-83T8-KACC-0AUY
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement